

PROGRAM OBJECTIVE

The goal of the *PET Clinics* is to keep practicing radiologists and radiology residents up to date with current clinical practice in positron emission tomography by providing timely articles reviewing the state of the art in patient care.

TARGET AUDIENCE

Practicing radiologists, radiology residents, and other health care professionals who provide patient care utilizing radiologic findings.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

1. Review why PET imaging can be used in the detection, staging, planning, and management of prostate cancer.
2. Discuss the advantages of using PET imaging, both traditional and novel, in accurately assessing, diagnosing, treatment planning, and predicting prostate cancer recurrences.
3. Recognize PET imaging as an effective modality in the management and treatment of prostate cancer.

ACCREDITATION

The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The EOCME designates this journal-based CME activity for a maximum of 9 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals requesting continuing education credit for this enduring material will be issued a certificate of participation.

DISCLOSURE OF CONFLICTS OF INTEREST

The EOCME assesses conflict of interest with its instructors, faculty, planners, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by EOCME for fair balance, scientific objectivity, and patient care recommendations. EOCME is committed to providing its learners with CME activities that promote improvements or quality in healthcare and not a specific proprietary business or a commercial interest.

The planning committee, staff, authors, and editors listed below have identified no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Aadil Adnan, MD; Abass Alavi, MD, MD (Hon), PhD (Hon), DSc (Hon); Sandip Basu, MBBS (Hons), DRM, Diplomate N.B., MNAMS; Austin J. Borja, MD; Indraje D. Dev; Liang Dong, MD; Heying Duan, MD; Poul Flemming Høilund-Carlsen, MD, PhD, DMSc, Prof (Hon); Cong Hu, MD; Andrei Iagaru, MD; Kevin Yu Jin, MD; Benjamin Koa, MD; Esha Kotheekar, MD; Mohana Manoj Krishnamoorthy; Angie Kuang, MS; Harshad Kulkarni, MD; Hui Chong Lau, MD; Siavash Mehdizadeh Seraj, MD; Nancy Mohsen, MD; Sze Jia Ng, MD; Peter Sang Uk Park, MD; Ameya D. Puranik, DNB; William Y. Raynor, MD; Mona-Elisabeth Rheheim, MD, PhD, MHA; Chaitanya Rojulpote, MD; Ali Salavati, MD; Sachi Singhal, MD; Lilja B. Solnes, MD, MBA; Raheleh Taghvaei, MD; Doreen Thomas-Payne, MSN, BSN, RN, PMHNP-BC; Thomas J. Werner, MSE; Rudolf A. Werner, MD; Wei Xue, MD; Vincent Zhang

The planning committee, staff, authors, and editors listed below have identified financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Michael A. Gorin, MD: *Researcher*: Progenics Pharmaceuticals, Inc.; *Consultant*: Lantheus Pharmaceuticals, Inc., Blue Earth Diagnostics, Inc.; *Speaker*: Lantheus Pharmaceuticals, Inc.

Kenneth J. Pienta, MD: *Researcher*: Progenics Pharmaceuticals, Inc.

Martin G. Pomper, MD, PhD: *Royalties and Patent Beneficiary*: Lantheus Pharmaceuticals, Inc.; *Researcher*: Progenics Pharmaceuticals, Inc.

Steven P. Rowe, MD, PhD: *Researcher*: Progenics Pharmaceuticals, Inc.; *Consultant*: Lantheus Pharmaceuticals, Inc., Novartis AG; *Speaker*: Lantheus Pharmaceuticals, Inc.

Bital Savir-Baruch, MD: *Consultant*: Blue Earth Diagnostics, Inc., GE Healthcare; *Researcher*: Blue Earth Diagnostics, Inc.

David M. Schuster, MD, FACR: *Consultant*: AIM Specialty Health, Global Medical Solutions Taiwan, Progenics Pharmaceuticals, Inc., Syncona; *Researcher*: Advanced Accelerator Applications, Amgen Inc., Blue Earth Diagnostics, Ltd, FUJIFILM Pharmaceuticals U.S.A., Inc, Nihon MediPhysics Co, Ltd., Telix Pharmaceuticals (US) Inc.

UNAPPROVED/OFF-LABEL USE DISCLOSURE

The EOCME requires CME faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinions. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labelling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

TO ENROLL

To enroll in the *PET Clinics* Continuing Medical Education program, call customer service at 1-800-654-2452 or sign up online at <http://www.theclinics.com/home/cme>. The CME program is available to subscribers for an additional annual fee of USD 254.00

METHOD OF PARTICIPATION

In order to claim credit, participants must complete the following:

1. Complete enrolment as indicated above.
2. Read the activity.
3. Complete the CME Test and Evaluation. Participants must achieve a score of 70% on the test. All CME Tests and Evaluations must be completed online.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.